Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404247 | 0.92 | KDM4E (0.56) | KDM4EPDE4BMAPTTHRBGPR119 | |
| SCHEMBL5769083 | 0.81 | GPR119 (0.49) | KDM4EMAPTGPR119 | |
| SCHEMBL29051731 | 0.76 | KDM4E (0.53) | KDM4EPDE4BMAPTTHRBGPR119 | |
| SCHEMBL17037848 | 0.76 | CHRM2 (0.40) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL4414698 | 0.75 | CHRNA1 (0.53) | KDM4EPDE4BMAPTTHRBGPR119 | |
| SCHEMBL17376133 | 0.75 | PDE4B (0.51) | KDM4EPDE4BMAPTTHRBGPR119 | |
| SCHEMBL4891329 | 0.75 | ESR2 (0.47) | KDM4EPDE4BMAPTTHRBGPR119 | |
| SCHEMBL25191447 | 0.75 | STS (0.44) | KDM4EPDE4BGPR119 | |
| SCHEMBL17398401 | 0.74 | KDM4E (0.53) | KDM4EMAPTTHRBGPR119PTPN2 | |
| SCHEMBL9884519 | 0.74 | NR1H2 (0.49) | KDM4EPDE4BMAPTTHRBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020616-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2005-01-27 | — | — | US | claimed |
| EP-1648872-A2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005007630-A2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050020616-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020616-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | KDM4E 783/4885PDE4B 1032/4885MAPT 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.